| Comprehensive genomic profiles of small cell lung cancer J George, JS Lim, SJ Jang, Y Cun, L Ozretić, G Kong, F Leenders, X Lu, ... Nature 524 (7563), 47-53, 2015 | 1959 | 2015 |
| ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers K Bergethon, AT Shaw, SH Ignatius Ou, R Katayama, CM Lovly, ... Journal of clinical oncology 30 (8), 863-870, 2012 | 1940 | 2012 |
| The national lung screening trial: overview and study design National Lung Screening Trial Research Team Radiology 258 (1), 243-253, 2011 | 1312 | 2011 |
| Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data CM Rudin, JT Poirier, LA Byers, C Dive, A Dowlati, J George, JV Heymach, ... Nature Reviews Cancer 19 (5), 289-297, 2019 | 827 | 2019 |
| Proteomic patterns of tumour subsets in non-small-cell lung cancer K Yanagisawa, Y Shyr, BJ Xu, PP Massion, PH Larsen, BC White, ... The Lancet 362 (9382), 433-439, 2003 | 811 | 2003 |
| A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo LR Saunders, AJ Bankovich, WC Anderson, MA Aujay, S Bheddah, ... Science translational medicine 7 (302), 302ra136-302ra136, 2015 | 545 | 2015 |
| Lung cancer screening, version 3.2018, NCCN clinical practice guidelines in oncology DE Wood, EA Kazerooni, SL Baum, GA Eapen, DS Ettinger, L Hou, ... Journal of the National Comprehensive Cancer Network 16 (4), 412-441, 2018 | 541 | 2018 |
| Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer J Amann, S Kalyankrishna, PP Massion, JE Ohm, L Girard, H Shigematsu, ... Cancer research 65 (1), 226-235, 2005 | 525 | 2005 |
| Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma NJ Wang, Z Sanborn, KL Arnett, LJ Bayston, W Liao, CM Proby, IM Leigh, ... Proceedings of the National Academy of Sciences 108 (43), 17761-17766, 2011 | 489 | 2011 |
| Integrating genomic features for non-invasive early lung cancer detection JJ Chabon, EG Hamilton, DM Kurtz, MS Esfahani, EJ Moding, H Stehr, ... Nature 580 (7802), 245-251, 2020 | 452 | 2020 |
| Tumour angiogenesis regulation by the miR-200 family CV Pecot, R Rupaimoole, D Yang, R Akbani, C Ivan, C Lu, S Wu, HD Han, ... Nature communications 4 (1), 2427, 2013 | 434 | 2013 |
| Significance of p63 amplification and overexpression in lung cancer development and prognosis PP Massion, PM Taflan, SM Jamshedur Rahman, P Yildiz, Y Shyr, ... Cancer research 63 (21), 7113-7121, 2003 | 419 | 2003 |
| Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis EE Gardner, BH Lok, VE Schneeberger, P Desmeules, LA Miles, ... Cancer cell 31 (2), 286-299, 2017 | 408 | 2017 |
| Biomarkers in lung cancer screening: achievements, promises, and challenges LM Seijo, N Peled, D Ajona, M Boeri, JK Field, G Sozzi, R Pio, JJ Zulueta, ... Journal of Thoracic Oncology 14 (3), 343-357, 2019 | 405 | 2019 |
| The human tumor atlas network: charting tumor transitions across space and time at single-cell resolution O Rozenblatt-Rosen, A Regev, P Oberdoerffer, T Nawy, A Hupalowska, ... Cell 181 (2), 236-249, 2020 | 378 | 2020 |
| High‐throughput proteomic analysis of formalin‐fixed paraffin‐embedded tissue microarrays using MALDI imaging mass spectrometry MR Groseclose, PP Massion, P Chaurand, RM Caprioli Proteomics 8 (18), 3715-3724, 2008 | 374 | 2008 |
| Mass spectrometry to classify non–small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a … F Taguchi, B Solomon, V Gregorc, H Roder, R Gray, K Kasahara, ... Journal of the National Cancer Institute 99 (11), 838-846, 2007 | 368 | 2007 |
| Lung cancer screening DE Wood, GA Eapen, DS Ettinger, L Hou, D Jackman, E Kazerooni, ... Journal of the National Comprehensive Cancer Network 10 (2), 240-265, 2012 | 325 | 2012 |
| SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival M Hassanein, MD Hoeksema, M Shiota, J Qian, BK Harris, H Chen, ... Clinical cancer research 19 (3), 560-570, 2013 | 318 | 2013 |
| Airway PI3K pathway activation is an early and reversible event in lung cancer development AM Gustafson, R Soldi, C Anderlind, MB Scholand, J Qian, X Zhang, ... Science translational medicine 2 (26), 26ra25-26ra25, 2010 | 291 | 2010 |
